Processa Pharmaceuticals, Inc. Other Noncash Expense
Processa Pharmaceuticals, Inc. (PCSA) reported Other Noncash Expense of $17.40 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashExpense · last filed 2023-03-30
- Processa Pharmaceuticals, Inc. other noncash expense for the quarter ending 2022-12-31 was $10.40M.
- Processa Pharmaceuticals, Inc. other noncash expense for the quarter ending 2022-09-30 was $3.50M.
- Processa Pharmaceuticals, Inc. other noncash expense for the quarter ending 2015-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. other noncash expense for the quarter ending 2015-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. other noncash expense for fiscal 2022 was $17.40M.
- Processa Pharmaceuticals, Inc. other noncash expense for fiscal 2015 was $25.50K.
| Period end | Other Noncash Expense 3 month | Other Noncash Expense 6 month | Other Noncash Expense 9 month | Other Noncash Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $10.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $13.90M derived: sum of 2 quarters · filed 2023-03-30 | $17.40M 10-K · filed 2023-03-30 | |
| 2022-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $7.00M 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $3.50M 10-Q · filed 2022-08-11 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $0.00 derived: sum of 2 quarters · filed 2017-09-25 | $0.00 derived: sum of 3 quarters · filed 2017-09-25 | $25.50K 10-K · filed 2017-09-25 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | $0.00 derived: sum of 2 quarters · filed 2017-09-08 | $25.50K 10-Q · filed 2017-09-08 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-30 | $25.50K 10-Q · filed 2017-08-30 | ||
| 2015-03-31 | $25.50K 10-Q · filed 2017-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |